Sandoz, a Novartis division, is the pioneer in biosimilars

Our biosimilars have been used in clinical practice for over 10 years, are available in over 86 countries and have over 450 million patient-days of experience

HQ / BIO / 18-0032

References: 1. Schubert-Tennigkeit, A., & Kothare, S. Zarzio ®( Filgrastim) PSUR 16 Sep 2017 to 15 Mar 2018. 2. Zeldin, G., et al. Rituximab ®( GP2013) PSUR 15 Jun 2017- 17 Nov 2017. 3. Zeldin, G., et al. Omnitrope ®( Somatropin) PSUR 01 Oct 2017 to 31 Mar 2018. 4. Tolksdorf, J., et al. Etanercept( GP2015) PSUR P1( 23 Jun 2017 to 14 Jan 2018) 5. Zeldin, G., & Kamble, K. Binocrit( Erythropoietin / epoetin alfa) PSUR 01 Sep 2017 to 28 Feb 2018.